Bio-Techne Corporation (TECH)

NASDAQ: TECH · Real-Time Price · USD

50.68

0.33 (0.66%)

At close: May 01, 2025, 10:57 AM

0.66% (1D)

Bid	50.63
Market Cap	8.01B
Revenue (ttm)	1.2B
Net Income (ttm)	158.14M
EPS (ttm)	0.98
PE Ratio (ttm)	51.71
Forward PE	22.9
Analyst	Hold

Ask	50.72
Volume	251,270
Avg. Volume (20D)	2,024,303
Open	50.07
Previous Close	50.35
Day's Range	48.24 - 50.72
52-Week Range	46.01 - 85.57
Beta	1.45

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene ther...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 9, 1989

Employees 3,100

Stock Exchange NASDAQ

Ticker Symbol TECH

Website https://www.bio-techne.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for TECH stock is "Hold." The 12-month stock price forecast is $77.5, which is an increase of 52.92% from the latest price.

Stock Forecasts

Next Earnings Release

Bio-Techne Corporation is scheduled to release its earnings on May 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+3.72%

Bio-Techne shares are trading higher after the com... Unlock content with Pro Subscription

5 months ago

+4.36%

Bio-Techne shares are trading higher after Gemini Bioproducts acquired the company's product rights and inventory of selected fetal bovine serum.

News

1 day ago · zacks.com

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

18 hours ago · zacks.com

TECH Gears Up to Report Q3 Earnings: Here's What to Expect

Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.

2 weeks ago · zacks.com

Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase ...

1 month ago · zacks.com

Bio-Techne Opens New Customer Experience Centre in Germany

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

1 month ago · zacks.com

TECH Stock Might Rise Following the Leo Shipping Announcement

Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.

1 month ago · zacks.com

TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?

Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.

2 months ago · seekingalpha.com

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue gr...

2 months ago · zacks.com

EXEL or TECH: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investo...